Payment overview · 2025
General Payments
$183.74
8 reported records · 5 companies
Healthcare provider profile · identity verified
Kenneth W. Hawk, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OAKLAND, MD · NPI 1427047240
Verified facts
What the public records show
CMS Open Payments records show Kenneth W. Hawk, NP received $183.74 in general payments during 2025 across 8 reported records.
Exact Sciences Corporation accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $73.30 | 39.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.09 | 17.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.18 | 16.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $28.75 | 15.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.42 | 10.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.74 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.07 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.09 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 125 |
| Lisinopril | Lisinopril | 353 | 106 |
| Furosemide | Furosemide | 339 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 320 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 285 | 91 |
| Losartan Potassium | Losartan Potassium | 271 | 81 |
| Omeprazole | Omeprazole | 257 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 238 | 70 |
| Tramadol Hcl | Tramadol Hcl | 219 | 60 |
| Metformin Hcl | Metformin Hcl | 211 | 63 |
| Gabapentin | Gabapentin | 204 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 57 |
| Famotidine | Famotidine | 182 | 52 |
| Sertraline Hcl | Sertraline Hcl | 177 | 51 |
| Potassium Chloride | Potassium Chloride | 171 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 162 | 57 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 41 |
| Lorazepam | Lorazepam | 123 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 44 |
| Trazodone Hcl | Trazodone Hcl | 119 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 38 |
| Ezetimibe | Ezetimibe | 115 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 40 |
| Azithromycin | Azithromycin | 105 | 87 |
| Eliquis | Apixaban | 103 | 29 |
| Simvastatin | Simvastatin | 95 | 26 |
| Jardiance | Empagliflozin | 94 | 18 |
| Ozempic | Semaglutide | 94 | 22 |
| Alprazolam | Alprazolam | 84 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 19 |
| Montelukast Sodium | Montelukast Sodium | 82 | 25 |
| Glipizide | Glipizide | 81 | 21 |
| Atenolol | Atenolol | 78 | 26 |
| Ibuprofen | Ibuprofen | 78 | 29 |
| Allopurinol | Allopurinol | 75 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 23 |
| Pregabalin | Pregabalin | 67 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 23 |
| Warfarin Sodium | Warfarin Sodium | 66 | 14 |
| Spironolactone | Spironolactone | 65 | 20 |
| Januvia | Sitagliptin Phosphate | 63 | 14 |
| Mounjaro | Tirzepatide | 63 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 23 |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Prednisone | Prednisone | 57 | 35 |
| Synthroid | Levothyroxine Sodium | 56 | 13 |
| Amoxicillin | Amoxicillin | 55 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 17 |
| Colchicine | Colchicine | 51 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 22 |
| Cephalexin | Cephalexin | 50 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 17 |
| Clonidine Hcl | Clonidine Hcl | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Nystatin | Nystatin | 46 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 14 |
| Carvedilol | Carvedilol | 44 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 32 |
| Celecoxib | Celecoxib | 42 | 12 |
| Clonazepam | Clonazepam | 42 | 14 |
| Glimepiride | Glimepiride | 42 | 14 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 13 |
| Buspirone Hcl | Buspirone Hcl | 39 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 21 |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Methylprednisolone | Methylprednisolone | 37 | 31 |
| Valsartan | Valsartan | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Meloxicam | Meloxicam | 24 | 11 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 13 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.74 · 8 records | Exact Sciences Corporation | CAPLYTA, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, Omnipod, The Cologuard Plus Collection Kit, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error